Clinical Study to Investigate Psorax35 Supplementation in Patients With Psoriasis

Psoriasis Vulgaris Clinical Trial

Official title:

Randomized, Double Blind, Placebo Controlled Clinical Study to Investigate Efficacy of Psorax35 for Treatment of Psoriasis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03359577
• Other study ID #: Psorax35-H17
• Status: Completed
• Phase: N/A
• Start date: November 21, 2017
• Est. completion date: April 29, 2019

Study information

• Verified date: September 2020
• Source: Arctic Nutrition AS
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The main objective of this study is to establish the efficacy and safety of Psorax35 supplementation in patients with mild to moderate Psoriasis.

Description:

Psoriasis is a common, genetically predisposed, inflammatory and proliferative disease of the skin, the most characteristic lesions consisting of chronic, sharply demarcated, dull-red scaly plaques, particularly on extensor parts of limbs and in the scalp. Psoriasis can be divided into mild, moderate or severe psoriasis based on the extent of the skin changes

Psorax35, which is extracted from herring roe are shown to improve the condition of people with psoriasis.

The objective of this study is to investigate the effect, safety, and mechanism of action of Psorax35 on mild to moderate Psoriasis and comorbidities associated with psoriasis through a 32-weeks study.

The participants will be randomized into one of two arms; Psorax35 and Placebo. The study will include a total of 6 treatment visits involving Blood samples, Photo documentation, Psoriasis and Severity index (PASI), Body surface area (BSA), Physician's Static Global Assessment (PSGA), Life quality index (EQ-5D, VAS and DLQI), Blood pressure, Blood rate, Body Mass Index (BMI), Waist circumference, Waist/hip ratio, and 24 hrs dietary recall. At visit 4 Blood samples, Blood pressure, Blood rate, BMI, Waist circumference, Waist/hip ratio, and 24 hrs dietary recall are not included.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 64
• Est. completion date: April 29, 2019
• Est. primary completion date: August 24, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Female and male subjects at least 18 years old understanding Norwegian oral and written information

2. Diagnosis of mild to moderate psoriasis vulgaris for at least 6 months prior to mild to moderate Psoriasis vulgaris as defined at screening by:

• PASI scores less than 10 (mild psoriasis) and

• Body surface area affected by chronic plaque psoriasis 1%-9.9% (mild and moderate psoriasis)

3. Women of childbearing potential must have a negative serum pregnancy test at the screening visit.

Exclusion Criteria:

1. Pregnancy

2. Initiation of a drug known to cause or exacerbate psoriasis

3. Having received an investigational medical product (IMP) or investigational device within 28 days' prior randomization

4. Alcohol and drug abuse or any condition associated with poor compliance

5. Malabsorption disorder

6. Scheduled hospitalization during the course of the study that could compromise the study

7. Major diseases or infections

8. Known or suspected sensitivity or allergic reactions to the IMP or excipients

9. Presence of other major medical or psychiatric illness that would affect the ability to participate in the study or put the subject at increased risk

10. Planned trip abroad to a sunny resort involving active sun exposure

11. Any anti psoriatic treatment

12. Immunosuppressive - immunomodulating treatment given for any other reason than psoriasis

13. UV treatment and return from a sunny resort involving active sun exposure for the last 4-6 weeks

Related Conditions & MeSH terms

• Psoriasis
• Psoriasis Vulgaris

Intervention

Dietary Supplement:
• Psorax35
This is a randomized, 32 weeks, single center, placebo controlled, double blind study to investigate Psorax35 supplementation in patients with mild to moderate Psoriasis. Groups of patients will be block randomized using randomly selected block sizes, and stratified according to gender.
• MCT oil
This is a randomized, 32 weeks, single center, placebo controlled, double blind study to investigate Psorax35 supplementation in patients with mild to moderate Psoriasis. Groups of patients will be block randomized using randomly selected block sizes, and stratified according to gender.

Locations

Country	Name	City	State
Norway	Haukeland Universitetssjukehus	Bergen

Sponsors (3)

Lead Sponsor	Collaborator
Arctic Nutrition AS	Haukeland University Hospital, University of Bergen

Country where clinical trial is conducted

Norway, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in PASI	Change from baseline in PASI in the Psorax35 group as compared to Placebo at week 32.	Baseline to 32 weeks
Secondary	Change in PASI over 24 weeks	Change from baseline in PASI in the Psorax35 group as compared to Placebo at week 6, 12, 18, and 24.	Baseline to 24 weeks
Secondary	Number of patients achieving PASI<3	Number of patients achieving PASI<3 in the Psorax35 group as compared to Placebo at week 6, 12, 18, 24, and 32.	Baseline to 32 weeks
Secondary	Improvement in PASI	Difference in 50% improvement in PASI (PASI-50), difference in 75% improvement in PASI (PASI-75) and difference in 90% improvement in PASI (PASI-90) from baseline in the Psorax35 group as compared with Placebo group at week 6, 12, 18, 24, and 32.	Baseline to 32 weeks
Secondary	Change in Physician's Static Global Assessment (PSGA)	Changes from baseline in PSGA=0-1 demonstrating clear or almost clear skin in the Psorax35 group as compared to Placebo group at week 6, 12, 18, 24, and 32.	Baseline to 32 weeks
Secondary	Change in Dermatology Life Quality Index (DLQI)	Changes from baseline in DLQ index in the Psorax35 group as compared to Placebo at week 6, 12, 18, 24, and 32.	Baseline to 32 weeks
Secondary	Change in EuroQoL 5 index (EQ-5D)	Change from baseline in EuroQoL 5 index in the Psorax35 group as compared to Placebo group at week 6, 12, 18, 24, and 32.	Baseline to 32 weeks
Secondary	Change in Visual analogue scale (VAS) score	Changes from baseline in VAS Scores (pruritus, pain skin/joints, stinging and total health condition (general/skin)) in the Psorax35 group as compared to Placebo at week 6, 12, 18, 24, and 32.	Baseline to 32 weeks
Secondary	Changes in highly sensitive C-reactive protein	Changes from baseline in highly sensitive C-reactive protein (mg/L) in the Psorax35 group as compared to Placebo at week 12, and 32.	Baseline to 32 weeks
Secondary	Adverse Events (AE) and Severe Adverse Events (SAE)	Monitoring of AEs and SAEs.	Baseline to week 32
Secondary	Changes in fasting serum lipids	Changes from baseline in serum lipids (Triacylglycerol (TAG), total cholesterol (TK), HDL-cholesterol, LDL-cholesterol, free-cholesterol, phospholipids, non-esterified fatty acids, non-HDL-cholesterol - mmol/L) and lipid ratios (TAG/TK ratio, HDL-chol/LDL-chol ratio), in the Psorax35 group as compared to Placebo at week 6, 12, 24, and 32.	Baseline to 32 weeks
Secondary	Changes in fasting serum glucose	Changes from baseline in serum glucose (mmol/L) in the Psorax35 group as compared to Placebo at week 6, 12, 24, and 32	Baseline to 32 weeks
Secondary	Changes in fasting serum insulin and insulin C-peptide	Changes from baseline in serum insulin (mIE/L) and insulin C-peptide (nmol/L) in the Psorax35 group as compared to Placebo at week 12, and 32.	Baseline to 32 weeks
Secondary	Changes in fasting serum HbA1c	Changes from baseline in serum HbA1c (%) in the Psorax35 group as compared to Placebo at week 12, and 32.	Baseline to 32 weeks
Secondary	Changes in blood pressure	Changes from baseline in blood pressure (mmHg) in the Psorax35 group as compared to Placebo at week 6, 12, 24, and 32.	Baseline to 32 weeks
Secondary	Changes in heart rate	Changes from baseline in heart rate (bpm) in the Psorax35 group as compared to Placebo at week 6, 12, 24, and 32.	Baseline to 32 weeks
Secondary	Changes in Body Mass Index (BMI)	Changes from baseline in Body Mass Index (BMI) in the Psorax35 group as compared to Placebo at week 6, 12, 24, and 32.; Weight in kilograms and height in meters will be combined to report BMI in kg/m2	Baseline to 32 weeks
Secondary	Changes in waist/hip ratio	Changes from baseline in waist/hip ratio in the Psorax35 group as compared to Placebo at week 6, 12, 24, and 32.; Waist in centimeters and hip in centimeters will be combined to report waist/hip ratio.	Baseline to 32 weeks
Secondary	Changes in plasma cytokines including adipocytokines	Changes from baseline in plasma cytokines including adipocytokines (pg/mL) in the Psorax35 group as compared to Placebo group at week 12, and 32.	Baseline to 32 weeks
Secondary	Changes in serum antioxidant capacity	Changes from baseline in serum antioxidant capacity (nmol Trolox ekv./ul) in the Psorax35 group as compared to Placebo group at week 12, and 32.	Baseline to 32 weeks
Secondary	Changes in serum Vitamin D	Changes from baseline in serum Vitamin D (nmol/L) in the psorax35 group as compared to Placebo group at week 12, and 32.	Baseline to 32 weeks
Secondary	Difference in use of cream-based treatment	Difference in use of rescue medication from baseline in the Psorax35 group as compared to placebo group at week 6, 12, 18, 24, and 32.; Amount of cream-based treatment in grams and number of days treated will be combined to report the use.	Baseline to 32 weeks
Secondary	Changes in safety laboratory parameters including hematology, clinical chemistry	Changes from baseline in safety laboratory parameters including hematology (Hemoglobin-g/dL, Hematocrit, Erythrocytes-10^9/L, Leukocytes-10^9/L, Lymphocytes-10^9/L, Monocytes-10^9/L, Eosinophiles-10^9/L, Neutrophiles-10^9/L, Blood plates-10^9/L), and clinical chemistry (ALAT-u/L, lactate dehydrogenase-u/L, creatine kinase-u/L, creatinine-umol/L, gamma-glutamyltransferase-u/L).	Baseline to 32 weeks